Furuse K, Kinuwaki E, Motomiya M, Nishiwaki H, Hasegawa K, Kobayashi K, Kurita Y, Ohta K, Fukuoka M, Nakajima S
Dept. of Internal Medicine, National Kinki Central Hospital.
Gan To Kagaku Ryoho. 1994 Sep;21(12):1941-7.
A late Phase II clinical study of KW-2307, a new vinca alkaloid derivative, in previously untreated patients with non-small cell lung cancer was jointly carried out in 26 medical institutions. Of 80 enrolled cases, 75 cases were eligible, and PR was attained in 23 cases (30.7%). The main adverse effect of this drug, leukopenia (neutropenia), was observed in 62.7% (83.3%) of Grade 3 and 4 cases, but they recovered rapidly. In addition to decreased hemoglobin in 67% (Grade 3 in 5.7%) of the cases, adverse effects included slight disorder of hepatic function, anorexia, nausea and vomiting, fever, general fatigue, phlebitis, paresthesia and interstitial pneumonia. Peripheral neuropathy such as paresthesia occurred rarely and was slight, if any.
一项关于新型长春花生物碱衍生物KW-2307用于既往未接受治疗的非小细胞肺癌患者的II期晚期临床研究在26家医疗机构联合开展。在80例入组病例中，75例符合条件，23例（30.7%）达到部分缓解。该药物的主要不良反应为白细胞减少（中性粒细胞减少），在3级和4级病例中分别有62.7%（83.3%）出现，但恢复迅速。除67%的病例出现血红蛋白降低（5.7%为3级）外，不良反应还包括轻度肝功能紊乱、厌食、恶心和呕吐、发热、全身乏力、静脉炎、感觉异常和间质性肺炎。感觉异常等周围神经病变很少发生，即便发生也很轻微。
